Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:acquisition |
CINVANTI from Heron Therapeutics
|
| gptkbp:ceo |
Barry Quart
|
| gptkbp:clinical_trial |
ongoing
|
| gptkbp:employees |
over 100
|
| gptkbp:focuses_on |
pain management
|
| gptkbp:founded_in |
gptkb:2010
|
| gptkbp:headquarters |
gptkb:United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Heron TP
|
| gptkbp:industry |
gptkb:pharmaceuticals
|
| gptkbp:notable_products |
gptkb:CINVANTI
ZYNRELEF |
| gptkbp:partnership |
with various healthcare organizations
|
| gptkbp:research_focus |
novel formulations
|
| gptkbp:stock_symbol |
HRTX
|
| gptkbp:traded_on |
gptkb:NASDAQ
|
| gptkbp:website |
www.herontx.com
|
| gptkbp:bfsParent |
gptkb:Heron_UAV
|
| gptkbp:bfsLayer |
6
|